Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Assets (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Assets for 16 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • Quarterly Assets rose 12.14% to $1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, up 12.14% year-over-year, with the annual reading at $1.4 billion for FY2025, 12.14% up from the prior year.
  • Assets hit $1.4 billion in Q4 2025 for Ani Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.4 billion in Q4 2025 to a low of $463.8 million in Q1 2021.
  • Historically, Assets has averaged $924.6 million across 5 years, with a median of $874.6 million in 2023.
  • Biggest YoY gain for Assets was 67.31% in 2021; the steepest drop was 3.81% in 2021.
  • Year by year, Assets stood at $771.6 million in 2021, then fell by 1.49% to $760.1 million in 2022, then rose by 18.99% to $904.4 million in 2023, then surged by 42.02% to $1.3 billion in 2024, then grew by 12.14% to $1.4 billion in 2025.
  • Business Quant data shows Assets for ANIP at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.3 billion in Q2 2025.